|Videos|August 31, 2021
CLL: Venetoclax in the R/R Setting
Experts in chronic lymphocytic leukemia (CLL) discuss retreating patients with venetoclax.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
3
Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)
4
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
5